Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bio-Path Holdings, a biotechnology company, has entered into an agreement with Acorn CRO, an oncology-focused clinical research organization, to provide Bio-Path with a contract medical officer and potentially other clinical trial support services.
Subscribe to our email newsletter
Concurrent with the signing of the agreement, Bradley Somer will serve as Bio-Path’s medical officer and medical liaison for the conduct of the company’s upcoming Phase I clinical study of liposomal Grb-2 in refractory or relapsed acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome.
In addition to providing clinical support services, Acorn CRO provides resources for the conduct of oncology clinical trials, including project management, clinical data management, statistical analysis, medical and scientific writing as well as support services. The services agreement with Acorn CRO provides Bio-Path with the ability to access this broad range of services as needed in the conduct of its Phase I clinical trial, said Bio-Path.
Peter Nielsen, president and CEO of Bio-Path Holdings, said: “Acorn CRO is a clinical research organization that provides an excellent fit with Bio-Path’s needs. As we prepare to enter a Phase I clinical trial for our lead liposomal antisense cancer drug, it is important that the company have access to service capabilities needed for the conduct of the trial.”